The Open Access Journal of Science and Technology

Abstract

A Therapeutic Targeting Identification from Microarray Data and Quantitative Network Analysis

Author(s): Hongliang Hu, Qinghua Zhang, Shen Li, Xiaona Zhang, Junsong Han, Huasheng Xiao,David Yan,Jie Zheng,and Biaoru Li

Personalizedtherapyis“therightdrugfortherightpatientattherighttime”.Herewereportedacaseofpersonalized therapyusinggeneexpressionsignature(GES)relateddrugdiscoverytotreatapatientwithdrug-resistantmetastasesfrombreasttumor.Methods:AftermRNAobtainedfrommetastaticlivertissuewasperformedbymicroarray,GESofgenomicprofileswere uncoveredbybioinformaticstoolandtargetingdrugsrelatedwithGESwereminedbydrug-bank.Severaltargeting-drugsapproved byFDAwereselectedtotreatthepatient.Results:1198geneswereuncoveredforthehigherexpressionbytwo-foldtocompare normalliverspecimensinwhich10ofminedgeneswereidentifiedasset-1GESformetastasisand16ofgeneswereuncovered as set-2 directly for primary breast tumor. Drug-bank platform were used to discover drugs for target set-1/2 genes. Eventually, medropxyoprogesterone (MPA) targeting set-I gene and doxorubicin targeting set-2 gene were selected for the patient because the two drugs have already been approved by FDA. After doxorubicin and MPA were administered, patient’s metastatic-tumor showedcompleteresponse.Conclusions:Wenotonlyanalyzegenomicexpressionprofilesbutalsodiscoversensitivecompounds fordrug-resistanttumor.WesuccessfullyselectdrugsapprovedbyFDAtotreatthepatient.

Share this article